Relationship Between Renal Function and the Incidence of Adverse Events in Patients With Colorectal Cancer Receiving Oxaliplatin

被引:9
作者
Watanabe, Daichi [1 ]
Fujii, Hironori [1 ]
Yamada, Yunami [1 ]
Iihara, Hirotoshi [1 ]
Ishihara, Takuma [2 ]
Matsuhashi, Nobuhisa [3 ]
Takahashi, Takao [3 ]
Yoshida, Kazuhiro [3 ]
Suzuki, Akio [1 ]
机构
[1] Gifu Univ Hosp, Dept Pharm, Yanagido 1-1, Gifu 5011194, Japan
[2] Gifu Univ, Gifu Univ Hosp, Innovat & Clin Res Promot Ctr, Gifu, Japan
[3] Gifu Univ, Dept Surg Oncol, Grad Sch Med, Gifu, Japan
关键词
Oxaliplatin; creatinine clearance; adverse events; colorectal cancer; nausea; CAPECITABINE PLUS OXALIPLATIN; III COLON-CANCER; PHASE-III; 1ST-LINE TREATMENT; ADJUVANT TREATMENT; FLUOROURACIL; LEUCOVORIN; PHARMACOKINETICS; THERAPY; CHEMOTHERAPY;
D O I
10.21873/anticanres.13953
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background/Aim: To clarify whether renal dysfunction affects the incidence of adverse events associated with oxaliplatin, the present study was designed to investigate the relationship between creatinine clearance (Ccr) and the incidence of oxaliplatin-related adverse events. Patients and Methods: A total of 287 CRC patients who received the first cycle of oxaliplatin-based chemotherapy were eligible. Adverse events, including nausea, vomiting, neutropenia and thrombocytopenia, were graded, and the relationship between Ccr and the incidence of adverse events was examined using multivariable logistic regression analysis. Results: A multivariable analysis indicated that the incidence of grade >= 2 nausea increased, while the incidence of other adverse events tended to be higher, as the Ccr decreased. Particularly, renal dysfunction (Ccr <60 ml/min) was a significant risk factor for grade >= 2 nausea (p=0.042). Conclusion: Care should be taken to avoid adverse events associated with oxaliplatin in patients with renal dysfunction.
引用
收藏
页码:299 / 304
页数:6
相关论文
共 50 条
  • [31] The economic burden of common adverse events associated with metastatic colorectal cancer treatment in the United States
    Latremouille-Viau, Dominick
    Chang, Jane
    Guerin, Annie
    Shi, Sherry
    Wang, Ed
    Yu, Justin
    Ngai, Christopher
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (01) : 54 - 62
  • [32] Determinants of adjuvant oxaliplatin receipt among older stage II and III colorectal cancer patients
    Lund, Jennifer L.
    Stuermer, Til
    Sanoff, Hanna K.
    Brookhart, Alan
    Sandler, Robert S.
    Warren, Joan L.
    CANCER, 2013, 119 (11) : 2038 - 2047
  • [33] Bevacizumab increases the incidence of cardiovascular events in patients with metastatic breast or colorectal cancer
    Kapelakis, Ioannis
    Toutouzas, Konstantinos
    Drakopoulou, Maria
    Michelongona, Archontoula
    Zagouri, Flora
    Mpamias, Aristotle
    Pliatsika, Paraskevi
    Dimopoulos, Meletios-Athanasios
    Stefanadis, Christodoulos
    Tousoulis, Dimitrios
    HELLENIC JOURNAL OF CARDIOLOGY, 2017, 58 (03) : 215 - 219
  • [34] Clinical Analysis of Hypersensitivity Reactions to Oxaliplatin Among Colorectal Cancer Patients
    Shen, Yuping
    Li, Chunyan
    Liu, Weixing
    Mao, Wei
    Qian, Hong
    Wang, Hui
    Xu, Qing
    ONCOLOGY RESEARCH, 2018, 26 (05) : 801 - 807
  • [35] Impact of oxaliplatin-induced neuropathy in patients with colorectal cancer: a prospective evaluation at a single institution
    Dault, R.
    Rousseau, M. P.
    Beaudoin, A.
    Frenette, M. A.
    Lemay, F.
    Beauchesne, M. F.
    CURRENT ONCOLOGY, 2016, 23 (01) : E65 - E69
  • [36] Comparison of toxicity profiles of fluorouracil versus oxaliplatin regimens in a large population-based cohort of elderly patients with colorectal cancer
    Cen, P.
    Liu, C.
    Du, X. L.
    ANNALS OF ONCOLOGY, 2012, 23 (06) : 1503 - 1511
  • [37] Incidence of thromboembolic events in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy
    Mezi, Silvia
    Musio, Daniela
    Orsi, Errico
    de Felice, Francesca
    Verdinelli, Isabella
    Morano, Federica
    Raffetto, Nicola
    Tombolini, Vincenzo
    ACTA ONCOLOGICA, 2013, 52 (01) : 187 - 190
  • [38] Thromboembolic Events in Patients With Colorectal Cancer Receiving the Combination of Bevacizumab-Based Chemotherapy and Erythropoietin Stimulating Agents
    Roddy, Julianna V. F.
    Partridge, Suzanne M.
    Rockey, Michelle L.
    Pruemer, Jane M.
    Guo, Jeff J.
    Desai, Shaili J.
    Safa, Malek M.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2010, 33 (01): : 36 - 42
  • [39] Incidence, severity, longitudinal trends and predictors of acute and chronic oxaliplatin-induced peripheral neuropathy in Taiwanese patients with colorectal cancer
    Hsu, Shu-Yi
    Huang, Wen-Shih
    Lee, Shu-Hui
    Chu, Tsui-Ping
    Lin, Yung-Chang
    Lu, Chang-Hsien
    Beaton, Randal D.
    Jane, Sui-Whi
    EUROPEAN JOURNAL OF CANCER CARE, 2019, 28 (02)
  • [40] In Vitro Schedule-Dependent Interaction Between Melphalan and Oxaliplatin in Human Colorectal Cancer Cell Lines
    van Iersel, Liselot B. J.
    Koudijs, Tamara M.
    Hoekman, Ellen J.
    Janssen-van Rhijn, Connie M.
    Vahrmeijer, Alexander L.
    Nortier, Johan W. R.
    van de Velde, Cornelis J. H.
    Gelderblom, Hans
    Kuppen, Peter J. K.
    JOURNAL OF SURGICAL RESEARCH, 2011, 167 (02) : 273 - 278